Free Trial
Tyler Van

Tyler Van Analyst Performance

Managing Director, Senior Biotech Equity Research Analyst at TD Cowen

Tyler Van is a stock analyst at TD Cowen focused in the medical sector, covering 7 publicly traded companies. Over the past year, Tyler Van has issued 9 stock ratings, including buy and hold recommendations. While full access to Tyler Van's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Tyler Van's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
9 Last 0 Years
Buy Recommendations
88.89% 8 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy88.9%8 ratings
Hold11.1%1 ratings
Sell0.0%0 ratings

Out of 9 total stock ratings issued by Tyler Van at TD Cowen, the majority (88.9%) have been Buy recommendations, followed by 11.1% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
6 companies
NYSE
14.3% of companies on NYSE
1 company

Tyler Van, an analyst at TD Cowen, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
85.7%
Manufacturing
1 company
14.3%

Tyler Van of TD Cowen specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
71.4%
MED - DRUGS
1 company
14.3%
PHARMACEUTICAL PREPARATIONS
1 company
14.3%

Tyler Van's Ratings History at TD Cowen

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5/5/2026Boost Price Target$43.73$60.00Buy
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/23/2026Boost Price Target$761.04$960.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4/7/2026Downgrade$52.23$53.00Hold
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3/12/2026Reiterated Rating$26.94Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
3/11/2026Boost Price Target$10.62$30.00Buy
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2/26/2026Reiterated Rating$2.75Buy
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2/26/2026Boost Price Target$27.06$35.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
2/26/2026Lower Price Target$36.82$85.00Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
11/5/2025Lower Price Target$8.28$15.00Buy